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THE EFFECT OF TOPIRAMATE (TPM) ON DURAL BLOOD
FLOW (DBF) IN MIGRAINEURS DURING AND AFTER AN
INFUSION OF NITROGLYCERIN (GTN). A. Amer, D. Wack, A.
Supala, L. A. Hershey, E. M. Bednarczyk, University at Buffalo,
Buffalo, NY.
BACKGROUND: Administration of nitric oxide (NO) donors
provides a reliable model of migraine induction. NO was reported to
cause a reproducible dilation of meningeal vessels and delayed in-
flammation in rat meninges. This may contribute to the pathogenesis
of migraine headaches. TPM, an anti-seizure drug, has shown effi-
cacy in migraine prophylaxis, however, the mechanism of this effect
is unclear. We studied the effect of GTN infusion on DBF in mi-
graineurs before and after an 8-week course of TPM.
METHODS: Migraineurs with and without aura (IHS criteria)
underwent measurement of DBF using 15O-water (H215O) and
positron emission tomography (PET). Measurements were made at
baseline and following stepwise infusion of GTN at 0.125, 0.25 and
0.5 mcg/kg/min (15 min at each dose step), and were repeated
following 8 w of treatment with a maximal dose of 100mg BID of
TPM. Quantitative measurement of blood flow was done in a series
of regions of interest (ROI) including an ROI inclusive of the dura
mater.
RESULTS: The following table shows DBF (mL/min/g) measure-
ments obtained from 8 migraineurs; mean (SD). ANOVA demon-
strated no statistically significant interaction between TPM and GTN
(p0.05).
Baseline 0.125* 0.25* 0.5*
30 min
post*
60 min
post*
Pre TPM 0.44 (0.1) 0.47 (0.1) 0.48 (0.2) 0.44 (0.1) 0.47 (0.1) 0.44 (0.1)
Post TPM 0.77 (0.6) 0.60 (0.2) 0.51 (0.1) 0.52 (0.2) 0.52 (0.2) 0.47 (0.1)
* GTN (mcg/kg/min).
CONCLUSIONS: Migraineurs, on or off TPM, did not show a
significant change in their DBF during and shortly after GTN infu-
sion. Delayed measurements of regional cerebral blood flow at dif-
ferent ROIs including the dura mater may reveal a possible involve-
ment of human meninges in migraine pathogenesis.
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TOBACCO SMOKING MODULATES BRAIN MU OPIOID
RELEASE. E. F. Domino, MD, D. J. Scott, BA, M. M. Heitzeg,
PhD, R. A. Koeppe, PhD, L. Ni, MS, S. K. Guthrie, PhD, J. Zubieta,
MD, PhD, University of Michigan, Ann Arbor, MI.
BACKGROUND/AIMS: The aim of this research was to prove
that tobacco smoking releases endogenous brain mu-opioids using
[11C]carfentanil, a selective mu-opioid agonist.
METHODS: Six healthy male tobacco smokers were abstinent
overnight for at least 10 hours before the scans, after which they
smoked denicotinized and average nicotine cigarettes (nicotine 0.08
and tar 9.1 mg and nicotine 1.01 mg and tar 9.5 mg, respectively).
Whole brain PET data were acquired, non-linear warped and coreg-
istered into ICBM space, and analyzed using SPM99.
RESULTS: Significant differences were found in [11C]carfen-
tanil displacement between the denicotinized and average nicotine
tobacco conditions. The initial hypothesis that smoking an average
nicotine cigarette in contrast to smoking a denicotinized cigarette
would release brain mu-opioids was confirmed. [11C]Carfentanil
binding was reduced in the right rostral and dorsal cingulate gyrus (p
0.03 and 0.001). Unexpectedly, decreased mu-opioid release also
was found with increased [11C]carfentanil binding in the left amyg-
dala and ventral striatum and right thalamus (p 0.0001).
CONCLUSIONS: These findings indicate a more complex role
for the endogenous brain mu-opioid system in human tobacco smok-
ing and indicate the need for further research.
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LONG-TERM EFFECTS OF RAMELTEON ON ENDOCRINE
FUNCTION IN PATIENTS WITH CHRONIC INSOMNIA IN A
DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY.
G. S. Richardson, MD, S. Wang-Weigand, MD, S. Sainati, MD, PhD,
S. Demissie, MSc, DrPH, Henry Ford Hospital Sleep Disorders and
Research Center, Takeda Global Research & Development Center,
Detroit, MI.
BACKGROUND: Ramelteon, an MT1/MT2 receptor agonist de-
veloped for insomnia treatment, was evaluated for long-term effects
on endocrine function.
METHODS: In a double-blind multicenter trial, 122 patients
(aged 18-45 yr) with chronic insomnia received placebo or ramelteon
16 mg nightly for 6 months. Multiple endocrine variables were
analyzed at baseline and monthly.
RESULTS: There were no consistent statistically significant dif-
ferences between treatments on measures of thyroid function (total
T4, free T4, TSH and total T3), adrenal function (AM cortisol and
ACTH), or on most reproductive endocrine measures (LH, FSH,
estradiol [women], total and free testosterone [men]). There were
small, but statistically significant, differences in prolactin levels be-
tween groups: overall mean change from baseline of 2.9 g/L (22.8%
change) with ramelteon and 0.6 g/L (4.4% change) with placebo.
The effect on prolactin appeared to be transient and was only seen in
women. No clinical signs of elevated prolactin were reported; aver-
age menstrual cycle length, duration of menses, and ovulation prob-
ability did not differ between groups. AE incidence was similar
between groups; most AEs were mild or moderate (3 patients had
SAEs unrelated to study drug).
CONCLUSION: Long-term treatment of chronic insomnia with
ramelteon had no appreciable effect on multiple measures of endo-
crine function compared to placebo. A mild, transient increase in
prolactin was observed in women, but it had no significant clinical
effect.
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SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK)
OF MULTIPLE DOSES OF LECOZOTAN, A NOVEL 5HT1A AN-
TAGONIST, IN HEALTHY ELDERLY SUBJECTS. V. Parks, Bsc,
S. V. Raje, PhD, A. A. Patat, MD, A. Plotka, MS, B. Astruc, MD, D.
Chassard, MD, Wyeth Pharmaceuticals France, Division Wyeth
Research, Wyeth Research, Wyeth, Biotrial, Aster-Cephac, Paris - La
De´fense Cedex, France.
BACKGROUND/AIMS: Lecozotan is a potent and silent 5-HT1A
antagonist being developed for the treatment of cognitive deficits
associated with Alzheimer’s disease. The objective of this study was
to assess the safety, tolerability, and PK of multiple oral doses of
Lecozotan in elderly subjects ( 65 yrs old), a population similar to
the target patient population.
METHODS: This was a randomized, double-blind, placebo-
controlled study in 16 subjects who received 5 mg q12h of Lecozotan
or placebo (12 active, 4 placebo) for 14 days. Safety evaluations
included adverse events (AE), vital signs, ECG, and lab tests up to 48
hours after the last dose. A complete PK profile was obtained on days
1 and 14.
RESULTS: Lecozotan was safe and well tolerated after multiple
dosing. Few mild to moderate AEs were recorded in 4 out of 16
subjects. There were no clinically significant changes in vital signs,
ECGs, and routine laboratory tests. Lecozotan tmax was  1 hour and
t1/2 was 9 - 11 hours. Steady-state Cl/F was 33 mL/h/kg. Steady-
state was achieved by day 3 of q12h administration and accumulation
ratio was 1.8. Mean steady-state AUC0-12h was within 13% of the
mean single-dose AUC0- suggesting reliable multiple-dose predict-
ability from single-dose PK. Cl/F in elderly was  25% lower in
comparison to young subjects.
CONCLUSIONS: Lecozotan was safe in elderly subjects up to
multiple daily doses of 10 mg and the elderly PK profile was
characterized by a mild decrease in clearance, which does not justify
any dosage adjustment.
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